4YL.F NANOFORM FINLAND OYJ
- Market cap
- EUR 60.5M
- P/E
- -
- P/B
- 1.78x
- ROE
- -39.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4YL.F undervalued?
Graham numberThe Graham number of NANOFORM FINLAND OYJ cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NANOFORM FINLAND OYJ fundamental analysis
No fundamental analysis for NANOFORM FINLAND OYJ yet.
NANOFORM FINLAND OYJ stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NANOFORM FINLAND OYJ
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosag…
Full company profileNANOFORM FINLAND OYJ financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NANOFORM FINLAND OYJ annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.95M | 3.49M | 2.57M | 2.78M | 3.55M | 4.10M |
| Gross Profit | 1.79M | 3.15M | 1.72M | 2.23M | 3.04M | 3.71M |
| Operating Income | -19.7M | -21.4M | -22.5M | -24.2M | -20.7M | -14.5M |
| EBITDA | - | -19.5M | -17.8M | -20.2M | -14.6M | -11.0M |
| Net Income | -19.7M | -22.1M | -20.8M | -23.4M | -17.9M | -14.3M |
| EPS | -0.27 | -0.28 | -0.26 | -0.27 | -0.21 | -0.17 |
| Balance Sheet | ||||||
| Total Assets | 99.4M | 101M | 78.1M | 71.8M | 54.0M | 48.0M |
| Total Liabilities | 14.9M | 13.4M | 11.2M | 11.8M | 11.2M | 11.7M |
| Shareholders' Equity | 84.5M | 87.2M | 66.9M | 60.0M | 42.8M | 36.3M |
| Cash & Short-term Investments | 75.7M | 68.7M | 14.2M | 36.5M | 24.0M | 19.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -14.3M | -20.1M | -18.0M | -18.3M | -17.7M | -10.0M |
| Capital Expenditure | 7.92M | 9.13M | 3.81M | 1.73M | 1.14M | 1.16M |
| Free Cash Flow | -22.3M | -29.2M | -21.8M | -20.0M | -18.8M | -11.2M |
| Ratios | ||||||
| ROE | -23.3% | -25.3% | -31.0% | -39.0% | -41.8% | -39.5% |
| ROA | -19.8% | -21.9% | -26.6% | -32.6% | -33.2% | -29.8% |
| Net Profit Margin | -1,007.4% | -633.0% | -808.7% | -843.3% | -504.7% | -349.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NANOFORM FINLAND OYJ dividends
NANOFORM FINLAND OYJ has not paid dividends in the last 5 fiscal years.
Who owns NANOFORM FINLAND OYJ
- Insiders 23.28%
- Institutions 33.96%
- Public & others 42.76%
- Shares outstanding 85.8M
- Free float 24.7M
NANOFORM FINLAND OYJ company profile
- Company name
- NANOFORM FINLAND OYJ
- Ticker
- 4YL.F
- ISIN
- FI4000330972
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 108
- Fiscal year end
- December
- Address
- Cultivator II, Helsinki, Finland, 00790
- Phone
- 358 2937 00150
- Website
- nanoform.com
About NANOFORM FINLAND OYJ
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles. It also offers STARMAP, an AI platform predicts the performance of your molecule in Nanoform's technology. The company was founded in 2008 and is headquartered in Helsinki, Finland.
NANOFORM FINLAND OYJ management
9- Mr. Albert Alexander HaeggstromCFO & Director · born 1971
- Prof. Edward Olof HaeggstromCo-Founder & CEO · born 1969
- Mr. Henri von HaartmanDirector of Investor Relations
- Mr. Peter HanninenGeneral Counsel & Chief Development Officer · born 1988
- Dr. David RoweHead of Manufacturing · born 1967
- Mr. Christian JonesChief Commercial Officer · born 1980
- Mr. Antonio Da SilvaChief of Business Operations · born 1974
- Ms. Johanna KauseChief Quality Officer · born 1971
- Dr. Jamie UnwinVice President of Strategic Insight